The Biotech Index ($IBB) is missing out on the rally that saw the market regain 2/3 of the losses. Sell-off appears over. Biotechs that fell enough to get Value Stock Group members to notice are the ones to watch. Exact Sciences ($EXAS) fell ~ 6% after the company reported revenue beating estimates. Cologuard revenue rose 168% to $266 million but the stock sold off on the news. Shorts have a 10.42% float position. $EXAS, Exact Sciences Corporation / H1 Regeneron ($REGN), which makes drugs for skin diseases, also faces challenges for Eylea. Novartis is competing to get into the market within two years. $REGN, Regeneron Pharmaceuticals, Inc. / H1 AbbVie ($ABBV) and Pfizer $PFE are vying for market share to treat eczema, which competes with REGN’s Dupixent. ABBV: $ABBV, AbbVie Inc. / H1 AVOID: Synergy Pharmaceuticals $SGYP fell below $2 again. Though it shows a “double bottom” on the chart, look at fundamentals. At the 7th Annual Global Healthcare Conference, SGYP could possibly write 4000 scripts a week by 2019. It has 200 sales staff or 20 scripts per salesman needed to get to that number. $SGYPQ, SYNERGY PHARMACEUTICALS INC DEL / H1 The underperformance of sales staff is hurting the stock. No buyout is likely for SGYP at this time.